Author

Sarah E. Ackermann

University of North Carolina at Chapel HillORCID 0000-0002-6898-7361Unclaimed ORCID profile · follow to get notified of new preprints

Biology Disciplines

Click to filter author papers

Cancer Biology· 2

Signature Assays, Organisms & Methods

Click to filter · or open tag

Approach:experimental assay· 2 Organism:human· 2 Assay:bulk RNA-seq· 1 Research Focus:drug response / drug discovery· 1

Frequent Co-Authors

Abigail S. KingiD· 1 shared Adriana IrizarryiD· 1 shared Alicia AlonsoiD· 1 shared Allyson J. OceaniD· 1 shared Ana M. MolinaiD· 1 shared Anastasia Murray TsomidesiD· 1 shared Andrea SboneriD· 1 shared Ashish SaxenaiD· 1 shared

Activity by Year

2025-2026 · peak 1/yr

Co-Author Collaboration Network

10 top collaborators · 45 mutual co-author links

Click any collaborator node to inspect or filter shared papers

Focal author (center)Selected co-authorORCID co-authorUnlinked name

Curved chords = mutual co-authorship

1 shared paperCancer Biology

Abigail S. KingORCID

Mutual co-authors in cluster

Author profile →

2 papers

Recent·Most cited

Cancer BiologybioRxivPreprintOct 23, 2026

Survivin Promotes the Formation of a Microtubule-Based Glycolytic Hub

Jacob Neumann, Wen-Hsuan Chang, Sarah E. Ackermann…·Marc A. Antonyak

This study identifies Survivin as a critical KRAS signaling partner that promotes glycolytic activity in PDAC cells by forming microtubule-based complexes with glycolytic enzymes.

DOI 10.64898/2026.08.28.747899

humanexperimental assay

𝕏 PostBluesky

Cancer BiologybioRxivPreprintApr 10, 2025

Pan-Cancer PDOs Preserve Tumor Heterogeneity and Uncover Therapeutic Vulnerabilities

Hui–Hsuan Kuo, Bhavneet Bhinder, Hamza Numan Gokozan…·M. Laura Martín

This study develops a pan-cancer PDO platform to preserve tumor heterogeneity and identify therapeutic vulnerabilities, finding that 58% of PDOs respond to Talazoparib and combination screens reveal resistance-overcoming drugs.

DOI 10.1101/2025.04.10.647635

humanbulk RNA-seq

𝕏 PostBluesky